Payment overview · 2025
General Payments
$188.19
8 reported records · 5 companies
Healthcare provider profile · identity verified
Vyjayanthi Atluri, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · BURR RIDGE, IL · NPI 1023067311
Verified facts
What the public records show
CMS Open Payments records show Vyjayanthi Atluri, MD received $188.19 in general payments during 2025 across 8 reported records.
PFIZER INC. accounted for 50.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Brilinta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 739 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $95.49 | 50.7% | 4 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $42.52 | 22.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.78 | 11.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.55 | 8.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.85 | 7.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $188.19 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $58.40 | 3 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $42.52 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $37.09 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.09 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 739 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
739 | 72 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 741 | 115 |
| Eliquis | Apixaban | 739 | 72 |
| Atorvastatin Calcium | Atorvastatin Calcium | 638 | 114 |
| Gabapentin | Gabapentin | 540 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 503 | 89 |
| Furosemide | Furosemide | 499 | 86 |
| Omeprazole | Omeprazole | 464 | 67 |
| Torsemide | Torsemide | 454 | 40 |
| Donepezil Hcl | Donepezil Hcl | 399 | 48 |
| Potassium Chloride | Potassium Chloride | 348 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 331 | 45 |
| Memantine Hcl | Memantine Hcl | 330 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 320 | 51 |
| Sertraline Hcl | Sertraline Hcl | 313 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 296 | 53 |
| Mirtazapine | Mirtazapine | 295 | 47 |
| Trazodone Hcl | Trazodone Hcl | 280 | 24 |
| Losartan Potassium | Losartan Potassium | 274 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 269 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 241 | 27 |
| Allopurinol | Allopurinol | 231 | 32 |
| Metformin Hcl | Metformin Hcl | 214 | 32 |
| Lisinopril | Lisinopril | 212 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 189 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 164 | 27 |
| Simvastatin | Simvastatin | 164 | 31 |
| Myrbetriq | Mirabegron | 163 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 157 | 18 |
| Carvedilol | Carvedilol | 146 | 23 |
| Midodrine Hcl | Midodrine Hcl | 146 | 17 |
| Xarelto | Rivaroxaban | 141 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 136 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 134 | 15 |
| Spironolactone | Spironolactone | 132 | 23 |
| Klor-Con M20 | Potassium Chloride | 125 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 118 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 118 | 15 |
| Benztropine Mesylate | Benztropine Mesylate | 107 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 92 | 12 |
| Latanoprost | Latanoprost | 88 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 85 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 80 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 14 |
| Tramadol Hcl | Tramadol Hcl | 77 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 75 | 14 |
| Famotidine | Famotidine | 75 | 15 |
| Lorazepam | Lorazepam | 75 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | suppressed |
| Atenolol | Atenolol | 66 | suppressed |
| Levetiracetam | Levetiracetam | 66 | suppressed |
| Jardiance | Empagliflozin | 63 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 61 | suppressed |
| Finasteride | Finasteride | 60 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 58 | 11 |
| Bumetanide | Bumetanide | 57 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 57 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 55 | suppressed |
| Gemtesa | Vibegron | 54 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 54 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 52 | suppressed |
| Sotalol | Sotalol Hcl | 52 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 34 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | suppressed |
| Enulose | Lactulose | 48 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 48 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 27 |
| Ezetimibe | Ezetimibe | 47 | suppressed |
| Januvia | Sitagliptin Phosphate | 47 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 46 | suppressed |
| Risperidone | Risperidone | 46 | suppressed |
| Nystatin | Nystatin | 44 | 27 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 43 | 15 |
| Prednisone | Prednisone | 43 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 35 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Brilinta | Ticagrelor | 34 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Timolol Maleate | Timolol Maleate | 33 | suppressed |
| Alprazolam | Alprazolam | 32 | 11 |
| Baclofen | Baclofen | 32 | suppressed |
| Cephalexin | Cephalexin | 32 | 21 |
| Hydrocortisone | Hydrocortisone | 31 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 29 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Trospium Chloride | Trospium Chloride | 28 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Nateglinide | Nateglinide | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | 15 |
| Digoxin | Digoxin | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 23 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 17 |
| Budesonide | Budesonide | 21 | suppressed |
| Erythromycin | Erythromycin Base | 21 | suppressed |
| Np Thyroid | Thyroid,pork | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 14 |
| Nyamyc | Nystatin | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Mesalamine | Mesalamine | 17 | suppressed |
| Rivastigmine | Rivastigmine | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Tacrolimus | Tacrolimus | 11 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $188.19 · 8 records | PFIZER INC. | AIRSUPRA, ELIQUIS, NURTEC ODT, Ozempic, PAXLOVID, REXULTI, Rybelsus, Zunveyl | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error